The content is available as a PDF (697.4 KB).
. 2022 Jun 16;162(7):S-1008. doi: 10.1016/S0016-5085(22)62390-4
Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
Brigid S Boland
, Benjamin Goodwin
, Zeli Zhang
, Nathaniel bloom
, Jennifer Neill
, Helen Le
, Angelina Collins
, Parambir Dulai
, Siddharth Singh
, Nghia H Nguyen
, Alba Grifoni
, Daniella Weiskopf
, John T Chang
, Jennifer M Dan
Brigid S Boland
Find articles by Brigid S Boland
Benjamin Goodwin
Find articles by Benjamin Goodwin
Zeli Zhang
Find articles by Zeli Zhang
Nathaniel bloom
Find articles by Nathaniel bloom
Jennifer Neill
Find articles by Jennifer Neill
Helen Le
Find articles by Helen Le
Angelina Collins
Find articles by Angelina Collins
Parambir Dulai
Find articles by Parambir Dulai
Siddharth Singh
Find articles by Siddharth Singh
Nghia H Nguyen
Find articles by Nghia H Nguyen
Alba Grifoni
Find articles by Alba Grifoni
Daniella Weiskopf
Find articles by Daniella Weiskopf
John T Chang
Find articles by John T Chang
Jennifer M Dan
Find articles by Jennifer M Dan
Issue date 2022 May.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9212360